Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer’s and Parkinson’s Diseases: Potential and Challenges

키워드

참고문헌 (83)

1. Wimo A, "The worldwide economic impact of dementia 2010", Alzheimers Dement, 9, pp.1~11 (2013)
2. R. Mayeux, "Epidemiology of Alzheimer Disease", Cold Spring Harbor Perspectives in Medicine, 2(8), pp.a006239~a006239 (2012), Cold Spring Harbor Laboratory[DOI]
3. de Lau LM, "Epidemiology of Parkinson’s disease", Lancet Neurol, 5, pp.525~535 (2006)
4. McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
5. Blacker D, "Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s disease. The National Institute of Mental Health Genetics Initiative", Arch Neurol, 51, pp.1198~1204 (1994)
6. Buchhave P, "Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia", Arch Gen Psychiatry, 69, pp.98~106 (2012)
7. Bateman RJ, "Clinical and biomarker changes in dominantly inherited Alzheimer’s disease", N Engl J Med, 367, pp.795~804 (2012)
8. Davies L, "A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques", Neurology, 38, pp.1688~1693 (1988)
9. Bezard E, "Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated", Trends Neurosci, 26, pp.215~221 (2003)
10. de la Fuente-Fernández R, "Role of DaTSCAN and clinical diagnosis in Parkinson disease", Neurology, 78, pp.696~701 (2012)
11. Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework", Clin Pharmacol Ther, 69, pp.89~95 (2001)
12. Peskind ER, "Safety and acceptability of the research lumbar puncture", Alzheimer Dis Assoc Disord, 19, pp.220~225 (2005)
13. Shaw LM, "Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics", Nat Rev Drug Discov, 6, pp.295~303 (2007)
14. Ross CA, "Protein aggregation and neurodegenerative disease", Nat Med, 10(Suppl), pp.S10~S17 (2004)
15. Selkoe DJ, "Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases", Nat Cell Biol, 6, pp.1054~1061 (2004)
16. Hardy J, "The amyloid hypothesis of Alzheimer’s disease:progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
17. Vigo-Pelfrey C, "Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease", Neurology, 45, pp.788~793 (1995)
18. Klein WL, "Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease", Neurobiol Aging, 25, pp.569~580 (2004)
19. Pyykkö OT, "Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus", PLoS One, 9, pp.e91974~ (2014)
20. Strozyk D, "CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study", Neurology, 60, pp.652~656 (2003)
21. Hampel H, "Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease", Alzheimers Dement, 4, pp.38~48 (2008)
22. Blennow K, "CSF markers for incipient Alzheimer’s disease", Lancet Neurol, 2, pp.605~613 (2003)
23. Tapiola T, "The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer’s disease", Neuroreport, 8, pp.3961~3963 (1997)
24. Snider BJ, "Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type", Arch Neurol, 66, pp.638~645 (2009)
25. Kester MI, "CSF biomarkers predict rate of cognitive decline in Alzheimer disease", Neurology, 73, pp.1353~1358 (2009)
26. Stomrud E, "Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly", Dement Geriatr Cogn Disord, 24, pp.118~124 (2007)
27. Tapiola T, "Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain", Arch Neurol, 66, pp.382~389 (2009)
28. Kang JH, "Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers", Clin Chem, 59, pp.903~916 (2013)
29. Shaw LM, "Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects", Ann Neurol, 65, pp.403~413 (2009)
30. Vanderstichele H, "Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative", Alzheimers Dement, 8, pp.65~73 (2012)
31. Fagan AM, "Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease", Biomark Med, 6, pp.455~476 (2012)
32. -AV-1451 (T807) on postmortem brain tissue, "Ann Neurol", 2015, 787~800
33. THK-5117 positron emission tomography, "PLoS One", 2015, e0140311~
34. Spillantini MG, "Alpha-synuclein in Lewy bodies", Nature, 388, pp.839~840 (1997)
35. Lashuel HA, "Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils", J Mol Biol, 322, pp.1089~1102 (2002)
36. Mollenhauer B, "α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism:a cohort study", Lancet Neurol, 10, pp.230~240 (2011)
37. Mollenhauer B, "Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects", Neurosci Lett, 532, pp.44~48 (2013)
38. Parnetti L, "Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease", Mov Disord, 29, pp.1019~1027 (2014)
39. Kang JH, "Association of cerebrospinal fluid β-amyloid 1-42, T-tau, Ptau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease", JAMA Neurol, 70, pp.1277~1287 (2013)
40. Shi M, "Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression", Ann Neurol, 69, pp.570~580 (2011)
41. Parkinson Progression Marker Initiative, "The Parkinson Progression Marker Initiative (PPMI)", Prog Neurobiol, 95, pp.629~635 (2011)
42. Hong Z, "DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease", Brain, 133(Pt 3), pp.713~726 (2010)
43. 김다나, "What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson’s disease? Is the Significance Diagnostic or Prognostic?", Experimental Neurobiology, 23(4), pp.352~364 (2014), 한국뇌신경과학회
44. Levy G, "The association of incident dementia with mortality in PD", Neurology, 59, pp.1708~1713 (2002)
45. Buter TC, "Dementia and survival in Parkinson disease: a 12-year population study", Neurology, 70, pp.1017~1022 (2008)
46. Siderowf A, "CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease", Neurology, 75, pp.1055~1061 (2010)
47. Alves G, "CSF Aβ42 predicts early-onset dementia in Parkinson disease", Neurology, 82, pp.1784~1790 (2014)
48. Mattsson N, "BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system", PLoS One, 7, pp.e31084~ (2012)
49. Mark Forman, "The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration", Alzheimer's & Dementia, 8(4), pp.P704~ (2012), Elsevier BV[DOI]
50. Mark Forman, "The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease", Alzheimer's & Dementia, 9(4), pp.P139~ (2013), Elsevier BV[DOI]
51. Kina Höglund, "MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE", Alzheimer's & Dementia, 10(4), pp.P447~ (2014), Elsevier BV[DOI]
52. Alexander R, "AZD3293 A novel BACE1 inhibitor: Safety, tolerability, and effects on plasma and CSF aβ peptides following single- and multiple-dose administration", Neurobiol Aging, 35(suppl 1), pp.S2~ (2014)
53. Doody RS, "A phase 3 trial of semagacestat for treatment of Alzheimer’s disease", N Engl J Med, 369, pp.341~350 (2013)
54. Fleisher AS, "Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease", Arch Neurol, 65, pp.1031~1038 (2008)
55. Siemers ER, "Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease", Neurology, 66, pp.602~604 (2006)
56. Siemers E, "Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers", Clin Neuropharmacol, 28, pp.126~132 (2005)
57. Coric V, "Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease", Arch Neurol, 69, pp.1430~1440 (2012)
58. Coric V, "Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial", JAMA Neurol, 72, pp.1324~1333 (2015)
59. Dockens R, "A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects", Clin Pharmacokinet, 51, pp.681~693 (2012)
60. Holland D, "Enrichment and stratification for predementia Alzheimer disease clinical trials", PLoS One, 7, pp.e47739~ (2012)
61. Blennow K, "Use of CSF biomarkers in Alzheimer’s disease clinical trials", J Nutr Health Aging, 13, pp.358~361 (2009)
62. Andreasen N, "First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer’s disease: a randomized, placebo-controlled study", PLoS One, 10, pp.e0098153~ (2015)
63. Doody RS, "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease", N Engl J Med, 370, pp.311~321 (2014)
64. Siemers ER, "Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients", Alzheimers Dement, 12, pp.110~120 (2016)
65. Vellas B, "Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU", US, Alzheimers Dement, pp.2013, 9[DOI]
66. Reiman EM, "Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments", J Alzheimers Dis, 26(Suppl 3), pp.321~329 (2011)
67. Ayutyanont N, "The Alzheimer’s prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers", J Clin Psychiatry, 75, pp.652~660 (2014)
68. Mills SM, "Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial", Rev Neurol (Paris), 169, pp.737~743 (2013)
69. 강주희, "Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease Modifying Therapies", The Korean Journal of Physiology & Pharmacology, 18(6), pp.447~456 (2014), 대한약리학회
70. Salloway S, "Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease", N Engl J Med, 370, pp.322~333 (2014)
71. Francois Bernier, "Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF", Alzheimer's & Dementia, 9(4), pp.P886~ (2013), Elsevier BV[DOI]
72. Joanne Bell, "A novel BACE inhibitor (PF-05297909): A two-part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta-amyloid in a first-in-human study", Alzheimer's & Dementia, 9(4), pp.P287~ (2013), Elsevier BV[DOI]
73. Turner RS, "A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease", Neurology, 85, pp.1383~1391 (2015)
74. Ross J, "CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebocontrolled study", Curr Alzheimer Res, 10, pp.742~753 (2013)
75. Jaren Landen, "Safety, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of Ponezumab in subjects with mild-to-moderate Alzheimer's disease", Alzheimer's & Dementia, 8(4), pp.P708~ (2012), Elsevier BV[DOI]
76. Jaren Landen, "Safety, tolerability, pharmacokinetics and pharmacodynamics of monthly and quarterly doses of Ponezumab (PF-04360365) in subjects with mild-to-moderate Alzheimer's disease", Alzheimer's & Dementia, 8(4), pp.P708~ (2012), Elsevier BV[DOI]
77. Craft S, "Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial", Arch Neurol, 69, pp.29~38 (2012)
78. Salloway S, "A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease", Neurology, 77, pp.1253~1262 (2011)
79. Parkinson Study Group SURE-PD Investigators, "Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial", JAMA Neurol, 71, pp.141~150 (2014)
80. Devos D, "Targeting chelatable iron as a therapeutic modality in Parkinson’s disease", Antioxid Redox Signal, 21, pp.195~210 (2014)
81. Paul G, "Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients", J Clin Invest, 125, pp.1339~1346 (2015)
82. Boxer AL, "Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2", 3 trial, 2014, pp.13, 676~685
83. Els Coart, "The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers", Alzheimer's & Dementia, 11(7), pp.P298~ (2015), Elsevier BV[DOI]

관련 논문AI추천